Death or nonfatal stroke in patients with acute myocardial infarction treated with tissue plasminogen activator. Participants in the National Registry of Myocardial Infarction 2

B G Angeja; A C Rundle; J H Gurwitz; J M Gore; H V Barron

doi:10.1016/s0002-9149(00)01441-7

Death or nonfatal stroke in patients with acute myocardial infarction treated with tissue plasminogen activator. Participants in the National Registry of Myocardial Infarction 2

Am J Cardiol. 2001 Mar 1;87(5):627-30, A9. doi: 10.1016/s0002-9149(00)01441-7.

Authors

B G Angeja¹, A C Rundle, J H Gurwitz, J M Gore, H V Barron

Affiliation

¹ Genentech Inc, South San Francisco, California, USA. bangeja@medicine.ucsf.edu

PMID: 11230850
DOI: 10.1016/s0002-9149(00)01441-7

Abstract

In a retrospective cohort of patients treated in community hospitals, tissue plasminogen activator (t-PA) was associated with decreased odds of in-hospital death or nonfatal stroke. However, the relative benefit was less evident in older patients and women, and some older subgroups did not benefit from treatment.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Age Factors
Aged
Aged, 80 and over
Cerebral Hemorrhage / chemically induced*
Cerebral Hemorrhage / mortality
Female
Hospital Mortality
Humans
Male
Middle Aged
Myocardial Infarction / drug therapy*
Myocardial Infarction / mortality
Randomized Controlled Trials as Topic
Risk Factors
Sex Factors
Tissue Plasminogen Activator / adverse effects*
Tissue Plasminogen Activator / therapeutic use

Substances

Tissue Plasminogen Activator